^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Excerpt:
Two other confirmed PRs were observed in a patient with glioblastoma (by the Revised Assessment for Neuro-Oncology Criteria) at 9 mg daily and a patient with endometrial cancer at the 12-mg intermittent dose with FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 (FGFR2-BICC1 and FGFR2-OFD1 occurred at similar frequency), respectively.
DOI:
10.1200/JCO.2014.60.7341
Trial ID: